Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Novo Nordisk A/S (NVO : NYSE)
 
 • Company Description   
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.

Number of Employees: 45,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $107.75 Daily Weekly Monthly
20 Day Moving Average: 1,781,700 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta: 0.47
52 Week High: $122.16
52 Week Low: $78.71
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.66% 6.58%
12 Week 4.87% 17.86%
Year To Date -3.79% 17.53%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Novo Alle 1
-
Bagsvaerd,G7 2880
DNK
ph: 45-4444-8888
fax: 45-4449-0555
dabo@novonordisk.com http://www.novonordisk.com
 
 • General Corporate Information   
Officers
Lars Fruergaard Jorgensen - President and Chief Executive Officer
Helge Lund - Chairman
Jeppe Christiansen - Vice chairman
Karsten Munk Knudsen - Executive Vice President and Chief Financial Offic
Kasim Kutay - Director

Peer Information
Novo Nordisk A/S (AGN.)
Novo Nordisk A/S (ABBV)
Novo Nordisk A/S (NVO)
Novo Nordisk A/S (LLY)
Novo Nordisk A/S (RHHBY)
Novo Nordisk A/S (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 670100205
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 1.00 (5.00:1)
Beta: 0.47
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 1.38%
Current Fiscal Quarter EPS Consensus Estimate: $0.86 Indicated Annual Dividend: $1.48
Current Fiscal Year EPS Consensus Estimate: $3.44 Payout Ratio: 0.44
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: 0.09
Estmated Long-Term EPS Growth Rate: 14.39% Last Dividend Paid: 03/25/2022 - $0.74
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 31.36
Trailing 12 Months: 32.07
PEG Ratio: 2.18
Price Ratios
Price/Book: 25.28
Price/Cash Flow: 29.66
Price / Sales: -
EPS Growth
vs. Year Ago Period: 6.82%
vs. Previous Quarter: 28.77%
Sales Growth
vs. Year Ago Period: 15.68%
vs. Previous Quarter: 7.52%
ROE
03/31/22 - 72.67
12/31/21 - 72.70
09/30/21 - 73.70
ROA
03/31/22 - 27.05
12/31/21 - 28.41
09/30/21 - 30.19
Current Ratio
03/31/22 - 0.91
12/31/21 - 0.86
09/30/21 - 1.03
Quick Ratio
03/31/22 - 0.69
12/31/21 - 0.66
09/30/21 - 0.82
Operating Margin
03/31/22 - 33.16
12/31/21 - 34.00
09/30/21 - 34.33
Net Margin
03/31/22 - 33.16
12/31/21 - 34.00
09/30/21 - 34.33
Pre-Tax Margin
03/31/22 - 40.97
12/31/21 - 41.96
09/30/21 - 43.21
Book Value
03/31/22 - 4.26
12/31/21 - 4.78
09/30/21 - 4.45
Inventory Turnover
03/31/22 - 1.26
12/31/21 - 1.23
09/30/21 - 1.24
Debt-to-Equity
03/31/22 - 0.36
12/31/21 - 0.18
09/30/21 - 0.19
Debt-to-Capital
03/31/22 - 26.57
12/31/21 - 15.48
09/30/21 - 15.79
 

Powered by Zacks Investment Research ©